CP and infectious disease: The CP therapy studies differed in the following aspects: patient demographics (eg, age, gender, and comorbidities), donors’ selection (ie, age, gender, diagnosis of SARS-CoV-2 infection and of recovery, and anti–SARS-CoV-2 antibody titer required for plasma donation), plasma collection and biologic qualification (number, volume and frequency of donations, infectious disease markers, and pathogen inactivation), and treatment and disease characteristics (dose and timing of administration, stage of the disease at which to start CP treatment).